Chandra Bhagat Pharma Ltd
Chandra Bhagat Pharma Ltd (CBPL) last reported results for the quarter ended Mar 2026, with sales of ₹91 crore and net profit of ₹3 crore. The stock last traded at ₹46.9, a market capitalisation of ₹35.4 crore, on a P/E of 11.6. Over the past 52 weeks the stock has ranged between ₹29.7 and ₹53. Figures are as of 6 Oct 2026 and are not real time.
Chandra Bhagat Pharma Ltd share price and key metrics
- Current price
- ₹46.9
- Market cap
- ₹35.4 cr
- Stock P/E
- 11.6
- Book value
- ₹43.9
- ROE
- 9.67%
- ROCE
- 12.1%
- Dividend yield
- 0.00%
- 52w high / low
- 53.0/29.7
Metrics as of 6 Oct 2026. Not real time.
Track Chandra Bhagat Pharma Ltd
Cruxal reads every Chandra Bhagat Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Chandra Bhagat Pharma Ltd growth and returns
- 10 Years
- 4%
- 5 Years
- 10%
- 3 Years
- -1%
- TTM
- 31%
- 10 Years
- 24%
- 5 Years
- 74%
- 3 Years
- 50%
- TTM
- 330%
- 10 Years
- %
- 5 Years
- -19%
- 3 Years
- -27%
- 1 Year
- 9%
- 10 Years
- 5%
- 5 Years
- 5%
- 3 Years
- 6%
- Last Year
- 10%
Chandra Bhagat Pharma Ltd quarterly results
In the quarter ended Mar 2026, sales were ₹91 cr, up 313.6% from ₹22 cr a year earlier.
| ₹ crore | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 44 | 75 | 119 | 102 | 65 | 22 | 26 | 91 |
| Expenses | 43 | 74 | 124 | 104 | 66 | 22 | 24 | 89 |
| Operating profit | 1 | 2 | -5 | -2 | -1 | -0 | 2 | 2 |
| OPM % | 2.3% | 2.4% | -4.2% | -2.0% | -1.8% | -1.2% | 7% | 2.4% |
| Other income | 1 | 0 | 7 | 4 | 3 | 2 | 0 | 3 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Profit before tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 |
| Tax % | 31% | 15% | 32% | 34% | -11% | 69% | 22% | 26% |
| Net profit | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 3 |
| EPS (₹) | 0.49 | 0.72 | 0.83 | 1.19 | 0.90 | 0.23 | 0.60 | 3.45 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Chandra Bhagat Pharma Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 90 | 97 | 106 | 94 | 71 | 94 | 120 | 221 | 89 | 116 |
| Operating profit | 4 | 5 | 5 | 3 | 4 | 3 | 3 | -7 | 1 | 4 |
| OPM % | 4.9% | 4.7% | 4.3% | 3.3% | 5% | 3.0% | 2.8% | -3.2% | 0.7% | 3.3% |
| Net profit | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 3 |
| EPS (₹) | 15.79 | 24.64 | 10.29 | 0.41 | 0.25 | 1.06 | 1.21 | 2.03 | 1.14 | 4.04 |
TTM is the trailing twelve months to the most recent quarter.
Chandra Bhagat Pharma Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 0.42 | 0.42 | 0.67 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 7 | 8 | 14 | 18 | 18 | 19 | 20 | 21 | 22 | 26 |
| Borrowings | 22 | 22 | 31 | 30 | 27 | 21 | 19 | 16 | 21 | 17 |
| Other liabilities | 26 | 28 | 37 | 19 | 19 | 25 | 14 | 56 | 51 | 45 |
| Total liabilities | 56 | 58 | 83 | 75 | 72 | 72 | 61 | 102 | 102 | 94 |
| Fixed assets | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 3 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 5 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Other assets | 51 | 56 | 78 | 74 | 71 | 72 | 60 | 99 | 99 | 90 |
| Total assets | 56 | 58 | 83 | 75 | 72 | 72 | 61 | 102 | 102 | 94 |
As reported by the company. Total assets equal total liabilities by construction.
Chandra Bhagat Pharma Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9 | -6 | 4 | -7 | 8 | 12 | 5 | 6 | -6 | 9 |
| Cash from investing | 0 | -0 | -0 | 0 | 0 | 0 | -0 | -2 | -1 | -0 |
| Cash from financing | 8 | 7 | -4 | 7 | -6 | -10 | -4 | -6 | 2 | -6 |
| Net cash flow | -1 | -0 | -0 | -0 | 2 | 3 | 1 | -1 | -4 | 2 |
| Free cash flow | -9 | -6 | 4 | -7 | 8 | 12 | 5 | 4 | -6 | 8 |
| CFO / operating profit | -200% | -129% | 98% | -238% | 229% | 440% | 164% | -94% | -805% | 250% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Chandra Bhagat Pharma Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 15% | 17% | 13% | 7% | 7% | 9% | 7% | 8% | 6% | 12% |
| Debtor days | 80 | 67 | 90 | 54 | 80 | 58 | 25 | 65 | 148 | 171 |
| Inventory days | 133 | 145 | 174 | 187 | 215 | 153 | 100 | 15 | 3 | 18 |
| Days payable | 81 | 69 | 117 | 53 | 79 | 12 | 11 | 23 | 45 | 124 |
| Cash conversion cycle | 132 | 143 | 146 | 188 | 216 | 199 | 114 | 57 | 107 | 65 |
| Working capital days | 125 | 138 | 83 | 148 | 177 | 104 | 75 | 36 | 101 | 77 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Chandra Bhagat Pharma Ltd shareholding pattern
Promoters held 73.02% at Mar 2026, up from 68.77% at Mar 2024. FIIs 0.00% and DIIs 0.00%.
| % held | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 69.09% | 68.24% | 68.69% | 68.77% | 69.29% | 71.20% | 72.19% | 73.02% |
| FIIs | 0.85% | 0.85% | 1.33% | 1.33% | 0.48% | 0.61% | 0.61% | 0.00% |
| DIIs | 0.00% | 0.00% | 0.89% | 0.89% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 30.07% | 30.91% | 29.09% | 29.02% | 30.23% | 28.18% | 27.20% | 26.99% |
| No. of shareholders | 126 | 146 | 134 | 152 | 315 | 316 | 301 | 280 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Chandra Bhagat Pharma Ltd corporate filings
- Notice of Closure of Trading WindowInsider Trading / SASTlow impact
- No financial or strategic corporate action reported; resignation of Company Secretary (CS) at Chandra Bhagat Pharma Limited with no immediate impact on financials or valuation.Company Updatelow impact
Cruxal's analysis: Chandra Bhagat Pharma Limited has announced the resignation of its Company Secretary, Ms…
Read the full analysis - Chandra Bhagat Pharma Limited shareholders approve preferential issuance of 66 lakh convertible warrantsAGM/EGMhigh impact
Cruxal's analysis: Chandra Bhagat Pharma Limited has successfully concluded its Annual General Meeting…
Read the full analysis - Chandra Bhagat Pharma Limited Proposes Preferential Issue of 66 Lakh Convertible WarrantsAGM/EGMhigh impact
Cruxal's analysis: Chandra Bhagat Pharma Limited has announced the proceedings of its 23rd Annual General…
Read the full analysis - Chandra Bhagat Pharma Limited issues corrigendum to AGM notice regarding 66 lakh convertible warrantsCompany Updatelow impact
Cruxal's analysis: Chandra Bhagat Pharma Limited has issued a corrigendum to its Annual General Meeting…
Read the full analysis - Chandra Bhagat Pharma Limited Announces Preferential Issue of 66 Lakh Convertible Warrants to Raise INR 29.04 CroreAGM/EGMhigh impact
Cruxal's analysis: Chandra Bhagat Pharma Limited has announced a preferential issue of 66,00,000 convertible…
Read the full analysis - Chandra Bhagat Pharma Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Chandra Bhagat Pharma Ltd has filed its Annual Report for the financial year 2025-26. The…
Read the full analysis - Chandra Bhagat Pharma Announces 29.04 Crore Preferential Issue of Convertible Warrants and Authorized Capital ExpansionBoard Meetinghigh impact
Cruxal's analysis: Chandra Bhagat Pharma Limited has approved a significant capital infusion through the…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.